Ozempic could delay ageing, researchers suggest

Researchers have suggested that semaglutide, commonly known as Ozempic, a medication used for treating Type 2 diabetes and obesity, may also have the potential to slow the aging process. Prof. Harlan Krumholz from Yale School of Medicine highlighted that recent studies indicate the drug could address various health issues, including heart failure, arthritis, Alzheimer's, and cancer. The findings were presented at the European Society of Cardiology Conference 2024 and published in several medical journals. The studies involved over 17,600 participants aged 45 and older, who were either given semaglutide or a placebo for more than three years. Results showed that those on the drug had a lower mortality rate from all causes, including cardiovascular diseases and COVID-19. While the incidence of COVID-19 was similar between both groups, the death rate was lower among those taking semaglutide. The drug also demonstrated benefits in reducing adverse cardiovascular events and improving heart failure symptoms, regardless of weight loss. However, experts caution that semaglutide should not be viewed as a quick fix and should be used under medical supervision due to potential side effects, including nausea and gastrointestinal issues.

- Semaglutide (Ozempic) may slow aging and improve health outcomes.

- The drug has shown benefits in reducing mortality rates from various causes.

- It is effective in treating conditions like heart failure and obesity.

- Semaglutide should be used under medical supervision due to possible side effects.

- Recent studies involved over 17,600 participants and were presented at a major medical conference.